Sales

In 2010, we increased Group sales by 8% in constant currency and by 13% at actual rates to €15,972 million (2009: €14,164 million).

The chart shows the various influences on Fresenius’ Group sales. Very good organic growth of 7% was achieved, while acquisitions contributed 1%. Currency translation had a positive impact of 5%. More information can be found under capital, shareholders, articles of association.

There were no significant consequences from changes in product mix and from price effects. No significant changes are currently expected in these two factors in the foreseeable future.





Sales growth by region was as follows:

The largest regions in the Group are North America and Europe, contributing 44% and 41% of total sales, followed by Asia-Pacific with 8%, and Latin America and Africa with 5% and 2%, respectively. Germany contributed 21% to Group sales.

In North America, sales increased by 9% in constant currency, with organic growth of 8%. In Europe, sales were up 7% in constant currency, with organic growth of 6%. Excellent organic growth was again achieved in Asia-Pacific with 7% and in Latin America with 11%.

Sales growth in the business segments was as follows:

  • Fresenius Medical Care achieved sales of €9,091 million in 2010 (2009: €8,064 million), an increase of 13%. Organic growth was 6%, while acquisitions contributed 1%. Currency translation had a positive impact of 6%. Fresenius Medical Care achieved significant increases in constant currency in dialysis care (9%), growth in dialysis patients was 3%. The growth in dialysis care was mainly due to organic growth in treatments and higher average revenues per treatment.
  • Fresenius Kabi increased sales by 19% to €3,672 million (2009: €3,086 million). The company achieved organic growth of 12%, to which all regions contributed. This was notably driven by the excellent growth in North America, where new product launches and strong demand due to supply constraints at competitors had a positive effect. Acquisitions contributed 1%. Currency translation impacted sales by 6%. This was mainly attributable to the strengthening of the currencies in North America, Brazil, and China against the euro.
  • Fresenius Helios increased sales by 4% to €2,520 million (2009: €2,416 million). Organic growth was 5%. This was mostly due to an increase in hospital admissions compared to 2009. The divestiture of an acute care clinic at the beginning of the year had an impact of 1%.
  • Fresenius Vamed achieved strong sales growth of 15% to €713 million (2009: €618 million). Organic growth was 15%. Sales in the project business increased by 16% to €487 million (2009: €420 million). Sales in the services business rose by 14% to €226 million (2009: €198 million).

SALES BY REGION


€ in millions 2010 2009 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
North America 7,020 6,113 15% 8% 6% 1% 44%
Europe 6,515 6,045 8% 6% 1% 1% 41%
Asia-Pacific 1,307 1,088 20% 7% 10% 3% 8%
Latin America 814 641 27% 11% 13% 3% 5%
Africa 316 277 14% 6% 8% 0% 2%
Total 15,972 14,164 13% 7% 5% 1% 100%

€ in millions 2010 2009 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
North America 7,020 6,113 15% 8% 6% 1% 44%
Europe 6,515 6,045 8% 6% 1% 1% 41%
Asia-Pacific 1,307 1,088 20% 7% 10% 3% 8%
Latin America 814 641 27% 11% 13% 3% 5%
Africa 316 277 14% 6% 8% 0% 2%
Total 15,972 14,164 13% 7% 5% 1% 100%

SALES BY BUSINESS SEGMENT


€ in millions 2010 2009 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
Fresenius Medical Care 9,091 8,064 13% 6% 6% 1% 57%
Fresenius Kabi 3,672 3,086 19% 12% 6% 1% 23%
Fresenius Helios 2,520 2,416 4% 5% 0% -1% 16%
Fresenius Vamed 713 618 15% 15% 0% 0% 4%

€ in millions 2010 2009 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
Fresenius Medical Care 9,091 8,064 13% 6% 6% 1% 57%
Fresenius Kabi 3,672 3,086 19% 12% 6% 1% 23%
Fresenius Helios 2,520 2,416 4% 5% 0% -1% 16%
Fresenius Vamed 713 618 15% 15% 0% 0% 4%

Order intake and order backlog in Fresenius Vamed’s project business again developed excellently: order intake rose by 16% to €625 million (2009: €539 million). Fresenius Vamed increased its order backlog by 18% to €801 million (December 31, 2009: €679 million). This assures a stable level of capacity utilization for Fresenius Vamed in the current year. Fresenius Vamed is the only business segment within the Fresenius Group whose business is significantly determined by order intake and order backlog. Driven by the continued strong demand for health care and hospital infrastructure, Fresenius Vamed was again able to sustain the trend in order intake and order backlog, as the overview below shows.

ORDER INTAKE AND ORDER BACKLOG − FRESENIUS VAMED

€ in millions 2010 2009 2008 2007 2006
Order intake 625 539 425 395 337
Order backlog (December 31) 801 679 571 510 387

€ in millions 2010 2009 2008 2007 2006
Order intake 625 539 425 395 337
Order backlog (December 31) 801 679 571 510 387

Continue reading:
Earnings structure

QUICKFINDER

History

Internal related Links

Tools